



N ACETYL-L- CYSTEINE AND ITS IMPORTANCE IN TODAYS WORLD

Medical Science

**Dr. Manjula
Raman PhD**

ABSTRACT

Vaccines are of utmost importance in preventing viral transmission especially among young people who are considered as carriers or spreaders of COVID -19. Yet again NAC an old drug with new approaches has undergone another milestone in medical world. It is a precursor of reduced glutathione. Its use to loosen thickening mucus in acute respiratory distress syndrome is well known and paracetamol intoxication can be contained by the high dose of intravenous NAC. It is a soluble thiol, a free radical scavenger, a GSH supplier, anti-inflammatory reaction participant. Thiols block the angiotensin converting enzyme-2 thus preventing penetration of SARS-CoV-2 directly into cells.

KEYWORDS

thiols, L-Cysteine, Glutathione, antioxidant,

COVID-19

COVID -19 caused by SARS-Cov-2 causes multisystem organ dysfunction leading to high mortality and morbidity. ARDS is the major cause of death in Covid-19 patients due to dysregulated host immune responses due to viral infection⁽¹⁾. Though new vaccines are used to contain its spread, its use in young volunteers produce neutralizing antibodies but not so effective in the elderly showing an age related immune response.

The use of NAC in COVID-19 patients has been fruitful because of its anti-inflammatory and immune-modulating behaviour. IL8 detected early in infected patients⁽³⁾ attracts neutrophils rapidly at sites of inflammation in the lungs that produce cytokines, enzymes elastase, ROS by oxidative burst, release DNA to form neutrophil extracellular traps-NETs traps⁽⁴⁾. A large neutrophil release is caused by large amounts of proinflammatory cytokines creating: "cytokine storm." – which has Reactive Oxygen Species (ROS). Neutrophils produce ROS radicals mainly superoxide radicals (O_2^-)

Neutrophil elastase (NE) degrades clotting factors and complement proteins and as a result pulmonary haemorrhage is seen in Covid-19 patients⁽²⁾. It degrades local plasminogen thus impairs fibrinolysis leading to intravascular coagulation and pulmonary embolism usually occur in ICU patients. Suppression of NE production by stabilising neutrophils or inhibiting neutrophil activation by IL-8 antibody can combat acute lung injury^(5,6)

Cellular immunity by way of oxidant-antioxidant balance is required by host to fight viral infection. Antioxidant like glutathione (GSH) is required to balance decreased glutathione (GSSG) in cells caused by increased ROS that inhibits T cell apoptosis. Reduced glutathione restores normal functions of immune cells reducing incidence and severity of pneumonia due to this virus infection⁽²⁾

NAC is an immunomodulating agent, a precursor of glutathione can also boost immune system suppress viral replication and reduce inflammation. NAC can improve compromised cell immunity and prevent development of certain respiratory viral diseases⁽⁷⁾

Can NAC administration benefit Covid-19 patients?

NAC offers the following to combat Covid-19

1. Antiviral functions of NAC inhibit NF- κ B activation in human lung epithelial cells⁽⁸⁾
2. It reduces the production of IL-8 and thus chemotactic migration of monocytes⁽⁹⁾
3. NAC inhibits replication of other viruses HIV⁽¹⁰⁾ and respiratory syncytial virus (RSV)⁽¹¹⁾. Guthappa suggested that NAC may bind to Cys-145 thus inhibit Mpro activity and viral replication. It can be the first line drug for SARS -Cov-2 due to its structural characteristics.

Immune Modulating properties of NAC.

1. NAC can replenish GSH redox balance in neutrophil which suppress NF κ B activation, cytokine production and chemotactic signals.⁽¹³⁾

2. Studies show NAC lowered rates of oxidative burst and chemotaxis, suppresses elastase release from neutrophils also reduces monocyte chemotaxis.⁽¹⁴⁾
3. Without affecting phagocytosis and bacterial killing function of neutrophils.⁽¹⁵⁾
4. NAC can increase GSH and block T- cell apoptosis via Fas antigen/fas ligand lethal signal.⁽¹⁶⁾
5. In higher doses, NAC increases GSH in lymphocytes during chronic inflammatory disease.⁽¹⁷⁾
6. It can reduce pneumonia and also significantly reduce TNF and MDA improving oxidative stress.⁽¹⁸⁾
7. It improves lung function to reduce mortality rate⁽¹⁹⁾. As it is a powerful scavenger of OH $^-$ prevents pulmonary oedema and respiratory failure^(20,21,22,23) suggesting high concentration enough prolonged use of NAC could help treat virus caused pneumonia and mediated sepsis. It can reduce viral replication and remove pneumocyte damage decrease immune responses in COVID -19 patients. So significance of NAC mediated treatments should be emphasized as part of a multimodal approach for home care COVID-19 patients.

CONCLUSION:

NAC is an inexpensive, dietary supplement, FDA approved many years ago. A holistic approach develops good immune system and a right antioxidant balance. Yoga and meditation are positive approaches to life de-stressors that maintain redox balance of glutathione, for persons treated at home and NAC is a good supplement given IV to patients in ICU along with antivirals. It can suppress viral replication and improve outcomes if timely used with other antiviral agents and can reduce hospital admission rate, mechanical ventilation and mortality.

REFERENCES

1. Jamwal S, Gautam A, Elsworth J, et al. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. *Life Sci*. 2020;257:118105.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–506.
3. Huang KJ, Su IJ, Theron M, et al. An interferon- γ -related cytokine storm in SARS patients. *J Med Virol*. 2005;75:185–194.
4. Stegelmeier AA, van Vloten JP, Mould RC, et al. Myeloid Cells during Viral Infections and Inflammation. *Viruses*. 2019;11(2):168.
5. Mukaida N, Matsumoto T, Yokoi K, et al. Inhibition of neutrophil-mediated acute inflammatory injury by an antibody against interleukin-8 (IL-8). *Inflammation Res*. 1998;47:151–157.
6. Bao Z, Ye Q, Gong W, et al. Humanized monoclonal antibody against the chemokine CXCL-8 (IL-8) effectively prevents acute lung injury. *Int Immunopharmacol*. 2010;10(2):259–263.
7. Flora SD, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. *Eur Respiratory J*. 1997;10(7):1535–1541.
8. Poppe M, Wittig S, Jurida L, et al. The NF- κ B-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells. *PLoS pathog*. 2017;13(3):e1006286.
9. Geiler J, Michaelis M, Naczek P, et al. N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. *Biochem Pharmacol*. 2010;79(3):413–420.
10. Ho W, Douglas SD. Glutathione and N-Acetylcysteine suppression of human immunodeficiency virus replication in human Monocyte/Macrophages in vitro. *AIDS Res Hum Retroviruses*. 1992;8(7):1249–1253.
11. Mata M, Sarrion I, Armengot M, et al. Respiratory syncytial virus inhibits ciliogenesis in differentiated normal human bronchial epithelial cells: effectiveness of N-Acetylcysteine. *PLoS One*. 2012;7(10):e48037.

- 12.. Guthappa R. Molecular Docking Studies of N-Acetyl Cysteine, Zinc Acetyl Cysteine and Niclosamide on SARS Cov 2 Protease and Its Comparison with Hydroxychloroquine. *Chemarxiv*. 2020.
13. SadowskaaAM,Mamel-y-KeenoyB,VertongenT,et al.Effect of N-Acetyl Cysteine on neutrophil activation markers in healthy volunteers:in vivo and in Vitro study. *Pharmacol Research* 2006;53(3);216-225
14. Kharazmi A. Nielsen H and Schiotx PO. N-acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. *Int J Lmmunopharmac.* 1988;10(1):39–46. doi:10.1016/0192-0561(88)90148-8
15. Allegra L,SarroMD Borio C, et al Human neutrophil oxidative bursts and their invitro modulation by different N Acetyl cysteine concentrations *Drug Res.*2002;52(9):669-676
16. Chi be.T.Takahasli S,Lato N,et a lFas-mediated apoptosis is modulated by intracellular glutathione in human T cells,*Eur Jour. Immunol* 1996;26(5):1164-1169
17. Lai Z,Hanczko R,Bonilla E,et al.N Acetyl cysteine reduces disease activity by blocking mammalian target of rapamycin in T- cells from SLE patients. A randomised double blinded placebo controlled trial. *Arthritis Rheumatology* 2012;64(8);2937-2946
18. Zhang Q,,Ju Y, Ma Y,et al N Acetyl Cysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia..A randomised controlled trial.*Medicine*,2018;97:e13087
19. Fox RB.Prevention of granulocyte-mediated oxidative lung injury in rats by a hydroxyl radical scavenger or dimethyl thiourea *J.Clin.Invest.*1984;74(4):1456-1464
20. Aruoma O ,Halliwell .B .Hoey BM,et al. The antioxidant activity of N Acetyl Cysteine its reaction with H2O2 ,hydroxyl radical, myeloperoxidase and HOCl. *Free Radical Biol Medi* 1989;6(6):593-597
21. Suter PM ,DomerighelliG, Schaller MD,et al,N Acetyl cysteine enhances recovery from acute lung injury in man: a randomized double blind placebo controlled clinical study *Chest* 1994;105(1):190-194
22. LaiK,NqW,ChanPK et al High dose N acetyl Cysteine therapy for novel H1N1 influenza Pneumonia *Ann Intern Medicine* 2010;152(16):687
23. MolnarZ,ShearerE,LoweD et al,N Acetyl cysteine treatment to prevent the pregression of multiorgan failure,a prospective randomized placebo controlled study *Crit Care Med*,1999;27(6):1100-1104